Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting the CREB pathway for memory enhancers.

Tim Tully1, Rusiko Bourtchouladze, Rod Scott

  • 1Helicon Therapeutics, Inc., One Bioscience Park Drive, Farmingdale, New York 11743, USA.

Nature Reviews. Drug Discovery
|April 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CREBB repression of protein synthesis in mushroom body gates long-term memory formation in <i>Drosophila</i>.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same author

Neuropeptide F inhibits dopamine neuron interference of long-term memory consolidation in <i>Drosophila</i>.

iScience·2021
Same author

CREBA and CREBB in two identified neurons gate long-term memory formation in <i>Drosophila</i>.

Proceedings of the National Academy of Sciences of the United States of America·2021
Same author

Protein S-acyl transferase 15 is involved in seed triacylglycerol catabolism during early seedling growth in Arabidopsis.

Journal of experimental botany·2019
Same author

A stress-enhanced model for discovery of disease-modifying gene: Ece1-suppresses the toxicity of α-synuclein A30P.

Neurobiology of disease·2018
Same author

Everyday memory: towards a translationally effective method of modelling the encoding, forgetting and enhancement of memory.

The European journal of neuroscience·2017

Millions suffer memory disorders, often misdiagnosed as Alzheimer's disease. Research into brain plasticity chemistry offers new targets for developing memory-enhancing drugs.

Area of Science:

  • Neuroscience
  • Pathology
  • Pharmacology

Background:

  • Memory disorders are often equated with Alzheimer's disease, but this represents only 50% of all dementias.
  • Dementias are the most severe form of learning and memory impairments, which can stem from various causes like heredity, disease, injury, or aging.
  • An estimated 30 million Americans experience clinically recognized memory disorders.

Purpose of the Study:

  • To highlight the discrepancy between the clinical perception of memory disorders and their actual prevalence and causes.
  • To underscore the limited therapeutic options currently available for Alzheimer's disease.
  • To introduce the emerging field of 'brain plasticity chemistry' as a promising avenue for novel memory enhancer development.

Main Methods:

  • Review of current clinical definitions and prevalence of memory disorders.

Related Experiment Videos

  • Analysis of the limitations of existing Alzheimer's disease treatments.
  • Exploration of recent advancements in basic neuroscience research focusing on brain plasticity.

    • Main Results:

    • Alzheimer's disease accounts for only half of all dementia cases.
    • Current pharmacological treatments for Alzheimer's disease are restricted to a single class of drugs.
    • Foundational research over 25 years has elucidated the 'chemistry of brain plasticity.'

    Conclusions:

    • There is a significant unmet need for broader treatments for memory disorders beyond Alzheimer's disease.
    • The understanding of brain plasticity chemistry provides a foundation for identifying new therapeutic targets.
    • Future drug discovery efforts can focus on these novel gene targets to develop effective memory enhancers.